Today's post is from Michael Geraci, supervisor, retirement consulting investment services.

Last year was a challenging one for the financial markets, resulting in volatility for most investment products. In fact, the coronavirus pandemic presented the biggest test for most asset allocation products since the 2008 financial crisis. 401(k) investments were no exception, specifically target-date funds.

Today's post is from Jim McAllister, director, equity research.

Two weeks ago, after several weeks of significant improvement, the medical news started to worsen as case growth and positive test rates ticked back up. Whether this situation might signal the start of another wave of infection growth was an open question. The good news is that the answer looks to be no. Case growth, while slightly above recent lows, has stayed steady despite the continued reopening of the economy and the increasing spread of more contagious variants of COVID-19. While the battle against the pandemic continues, vaccinations are also continuing. They should end up choking the virus off before it gets to a significant fourth wave. The medical risks are still real, but they are lower than they were two weeks ago, and they’re dropping every week.

“The number one problem in today’s generation and economy is the lack of financial literacy.” —Alan Greenspan

The first quarter looks to be the turning point, both for the pandemic here in the U.S. and for the economic damage it has caused. While risks still remain, especially in the short term, the significant progress we made in the first two months of the year started coming to fruition in March, signaling that we are through the worst of it.

We have had a lot of good economic news recently, including the significant bounce in consumer confidence reported by the Conference Board. Consumer confidence rose by more than 20 percent last month, to the highest level since September, before the third wave. According to that increase, people are feeling much better about the economy and their place in it.

I wanted to use the title “Leverage, Margin Calls, and Stock Prices, Oh My” here. But I decided to go with the more specific title so readers would actually know what I was taking about. Those are the real themes, though, as the hedge fund/private family office Archegos is simply the latest iteration of an old and sad story.

For the first time in several weeks, the big picture on the medical front has gotten worse. Case growth and positive test rates have ticked back up as the economy has reopened. While the change is relatively small so far, it is a reversal of previous improvements and signals that both reopening and the spread of more contagious variants are outpacing the positive effects of vaccinations. Faster spread has therefore moved from a potential risk to an actual one.

Today's post is from Anu Gaggar, senior investment research analyst.

Today's post was cowritten by Chris Stuart, senior investment research analyst.